Our data showing complete recovery of TSLPRCART functionality after ruxolitinib removal, including the ability to clear a CRLF2+ ALL relapse challenge, suggest that ruxolitinib maintenance therapy following TSLPRCART-induced leukemia remission could potentially prevent Ph-like and DS-ALL relapse while promoting long-term TSLPRCART persistence and remission durability and perhaps also minimizing antigen-loss relapse via antigen-independent targeting of critical intracellular signaling dependencies. The gene discussed is CRLF2; the disease is leukemia.